Company intelligence / Profile preview

QureBio Ltd.

Shanghai, Shanghai, Chinaqurebio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

QureBio’s lead program Q‑1802—a bispecific antibody targeting Claudin18.2 and PD-L1—has demonstrated excellent safety, tolerability, and preliminary anti-tumor activity in Phase I trials for relapsed/refractory solid tumors. The company has multiple additional programs at preclinical or IND stages targeting cancer and inflammation.

Therapeutic areas: OncologyImmunologyMetabolic Disorders
Modalities: Bispecific antibodiesMonoclonal antibodies (mAbs)Fusion proteinsTrispecific antibodies
Industry: Biotech

Drug pipeline

6 assets

q-1802

5 more assets in the full pipeline.

Request access →

Partnerships

BRL MedicineBioMapPrecision ScientificHengrui Pharmaceuticalsongoing collaborations with industry partners for novel therapeutics development.

Beyond the preview

Go deeper on QureBio Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QureBio Ltd..

Explore the full profile